Figure 4 - available via license: Creative Commons Attribution-NonCommercial 4.0 International
Content may be subject to copyright.
Forest plot of HR in lung cancer patients with brain metastases. (A) HR for progression-free survival of all patients with brain metastases; (B) HR for overall survival of all patients with brain metastases; (C) HR for progression-free survival of all patients without brain metastases; (D) HR for overall survival of all patients without brain metastases.
Source publication
Objectives:
Based on the acknowledged organ-specific immune microenvironment, little is known regarding the efficacy of immunotherapy in patients with lung cancer according to metastatic sites. This meta-analysis aimed to explore the efficacy of immune checkpoint inhibitors (ICIs) vs chemotherapy in patients with lung cancer with liver metastases...
Contexts in source publication
Context 1
... 2 =43.76%, p=0.07) versus chemotherapy alone. In a meta-analysis based on the results of 963 patients from 13 clinical trials, OS was significantly improved for administered ICIs (HR 0.71, 95% CI 0.53 to 0.94, p=0.02), with substantial heterogeneity (I 2 =65.05%, p<0.01) ( figure 4A,B). In patients without BM, the HR for OS and PFS of the individual studies and the combined results based on the random effects model are shown in figure 4C,D. ...
Context 2
... a meta-analysis based on the results of 963 patients from 13 clinical trials, OS was significantly improved for administered ICIs (HR 0.71, 95% CI 0.53 to 0.94, p=0.02), with substantial heterogeneity (I 2 =65.05%, p<0.01) ( figure 4A,B). In patients without BM, the HR for OS and PFS of the individual studies and the combined results based on the random effects model are shown in figure 4C,D. ICIs accounted for a 41% decreased risk of disease progression (95% CI 0.52 to 0.68, p<0.01; ...
Similar publications
Background
Prognostic nutritional index (PNI) has been identified as a reliable prognostic factor for cancer adjuvant therapy. However, its prognostic value in lung cancer patients receiving immune checkpoint inhibitors (ICIs) remains inconclusive.
Method
A systematic literature review and meta-analysis was performed based on online databases befo...
Citations
... Several trials have been done in metastatic non-small cell lung cancer with a recent meta-analysis of 10 phasethree trials showing that regimens containing ICI improved progression-free survival (HR 0.53, 95% CI 0.40-0.69, P < 0.01) versus chemotherapy alone [21]. ...
Brain metastases (BrM) develop in 20–40% of patients with advanced cancer. They mainly originate from lung cancer, melanoma, breast cancer, and renal cell carcinoma, and are associated with a poor prognosis. While patients with BrM traditionally lack effective treatment options, immunotherapy is increasingly gaining in importance in this group of patients, with clinical trials in the past decade demonstrating the efficacy and safety of immune checkpoint blockade in BrM originating from specific tumor types, foremost melanoma. The brain is an immune-specialized environment with several unique molecular, cellular, and anatomical features that affect immune responses, including those against tumors. In this review we discuss the potential role that some of these unique characteristics may play in the efficacy of immunotherapy, mainly focusing on the lymphatic drainage in the brain and the role of systemic anti-tumor immunity that develops due to the presence of concurrent extracranial disease in addition to BrM.
